OncoMatch/Clinical Trials/NCT07022002
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
Is NCT07022002 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including SSGJ-705 and PD-1/L1 inhibitor combined with chemotherapy for locally advanced, recurrent or metastatic malignancies.
Treatment: SSGJ-705 · PD-1/L1 inhibitor combined with chemotherapy · SSGJ-705 combined with chemotherapy — This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Monotherapy and Combination Therapy in patients with advanced HER2-Expressing Solid Tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: HER2 (ERBB2) overexpression
HER2-Expressing
Disease stage
Metastatic disease required
local advanced or metastatic
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
Inadequate organ or bone marrow function [excluded]
Kidney function
Inadequate organ or bone marrow function [excluded]
Liver function
Inadequate organ or bone marrow function [excluded]
Inadequate organ or bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07022002 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ERBB2?
Yes, ERBB2 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify